Sign inJoin waitlistJoin the waitlist

NH

Noah Hahn

Physician · Johns Hopkins School of Medicine

Credentials: · · · ·

History

Johns Hopkins School of Medicine
Present

Hematology and Medical Oncology
2003–2006
Internal Medicine
2000–2003
Indiana University School of Medicine
1996–2000

Research

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
New England Journal of Medicine · 2015 · 2,355 citations
Bladder cancer
Review · The Lancet · 2016 · 1,193 citations
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2…
The Lancet Oncology · 2017 · 1,061 citations

GS
Guru Sonpavde
39 papers
Max Kates
39 papers · 14 as a resident
TB
Trinity Bivalacqua
39 papers · 22 as a resident
Matthew Galsky
38 papers
JH
Jean Hoffman-Censits
33 papers
Andres Matoso
21 papers
CS
Christopher Sweeney
17 papers
Elizabeth Plimack
17 papers
Alexander Baras
16 papers
Petros Grivas
15 papers
WO
William Oh
15 papers
George Netto
14 papers

Grants

Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
National Cancer Institute · R01
Contact PI · $3.2M · Johns Hopkins University
2019–2026

Clinical trials

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020–2025
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Principal investigator · Active not recruiting · Phase 1, Phase 2
Noah Hahn, M.D.
2017–2029
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Principal investigator · Active not recruiting · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017–2027
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Study chair · Completed · Phase 2
Noah Hahn, M.D.
2013–2017